- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ZENAS BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| Di | Zenas BioPharma reports Q2 results | 1 | Seeking Alpha | ||
| Di | Zenas BioPharma, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| Di | Zenas BioPharma, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| Di | Zenas BioPharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| Di | Zenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Updates | 48 | GlobeNewswire (Europe) | - Topline results from pivotal Phase 3 INDIGO trial in Immunoglobulin G4-Related Disease expected around year-end 2025 - - Completed enrollment of Phase 2 MoonStone trial in Relapsing Multiple Sclerosis... ► Artikel lesen | |
| 10.07. | Citi reiterates Buy rating on Zenas Biopharma stock with $27 price target | 3 | Investing.com | ||
| 03.07. | Morgan Stanley assumes coverage on Zenas Biopharma stock with Overweight rating | 1 | Investing.com | ||
| 03.07. | Morgan Stanley nimmt Zenas Biopharma-Aktie mit Übergewichtung in Beobachtung auf | 4 | Investing.com Deutsch | ||
| 20.06. | Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 126 | GlobeNewswire (Europe) | WALTHAM, Mass., June 20, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in... ► Artikel lesen | |
| 12.06. | Zenas BioPharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 04.06. | Zenas BioPharma, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 15.05. | Zenas BioPharma, Inc. GAAP EPS of -$0.80, revenue of $10M | 1 | Seeking Alpha | ||
| 15.05. | Zenas BioPharma May 2025 slides: key data readouts expected by year-end | 1 | Investing.com | ||
| 15.05. | Zenas BioPharma, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 15.05. | Zenas BioPharma, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 15.05. | Zenas BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Updates | 89 | GlobeNewswire (Europe) | - Topline results from pivotal Phase 3 INDIGO trial in Immunoglobulin G4-Related Disease expected around year-end 2025 - - Phase 2 MoonStone trial in Relapsing Multiple Sclerosis enrollment concluding... ► Artikel lesen | |
| 17.04. | Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 169 | GlobeNewswire (Europe) | WALTHAM, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in... ► Artikel lesen | |
| 07.04. | Zenas BioPharma names new Chief Scientific Officer | 1 | Investing.com | ||
| 07.04. | Zenas BioPharma names Haley Laken as chief scientific officer | 1 | Seeking Alpha | ||
| 07.04. | Zenas BioPharma ernennt neuen Chief Scientific Officer | 1 | Investing.com Deutsch |
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AMGEN | 244,15 | +0,04 % | Amgen-Aktie läuft heute schlechter (245,9334 €) | Das Wertpapier von Amgen notiert am Mittwoch ein wenig leichter. Das Papier kostete zuletzt 285,90 US-Dollar. Für der Anteilsschein von Amgen steht gegenwärtig ein Abschlag von 4,84 Prozent zu Buche.... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 478,80 | +0,42 % | Truist Securities lowers Regeneron Pharma stock price target on Eylea concerns | ||
| BIOMARIN PHARMACEUTICAL | 48,640 | -0,12 % | Biomarin Pharmaceutical Inc. Bottom Line Rises In Q2 | WASHINGTON (dpa-AFX) - Biomarin Pharmaceutical Inc. (BMRN) announced a profit for its second quarter that Increases, from last yearThe company's earnings totaled $240.53 million, or $1.23 per... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 14,545 | -4,59 % | Arrowhead Pharma: Leerink Partners senkt Kursziel auf 21 US-Dollar | ||
| SWEDISH ORPHAN BIOVITRUM | 24,760 | +0,08 % | Sobi North America Announces Approval Of Doptelet For Pediatric ITP | STOCKHOLM (dpa-AFX) - Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB,
announced the FDA approved Doptelet or avatrombopag for the treatment of thrombocytopenia... ► Artikel lesen | |
| INSMED | 104,00 | 0,00 % | XFRA IM8N: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILINSMED INC. DL-... ► Artikel lesen | |
| SCHOLAR ROCK | 27,200 | -1,45 % | BMO Capital lowers Scholar Rock stock price target to $45 on Novo Catalent concerns | ||
| PROQR THERAPEUTICS | 1,691 | +3,62 % | ProQR Therapeutics N.V.: ProQR Announces Second Quarter 2025 Operating and Financial Results | Submitted CTA for lead program AX-0810, targeting NTCP for cholestatic diseasesAdvancing AX-2402 program toward clinical candidate selection, targeting MECP2 (R270X) for Rett SyndromeHosting fall... ► Artikel lesen | |
| CRINETICS PHARMACEUTICALS | 24,200 | -1,63 % | Crinetics Pharmaceuticals, Inc.: Crinetics Pharmaceuticals Announces August 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on August 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified... ► Artikel lesen | |
| VENTYX BIOSCIENCES | 2,630 | 0,00 % | Ventyx Biosciences, Inc.: Ventyx Biosciences Announces Positive Top-Line Data from its Phase 2a Safety and Biomarker Trial Evaluating VTX3232 in Patients with Early-Stage Parkinson's Disease | The study met its primary goal of establishing safety and tolerability of VTX3232 in patients with early-stage Parkinson's disease CSF and plasma exposures reinforce VTX3232's potential as a once-daily... ► Artikel lesen | |
| THERATECHNOLOGIES | 2,740 | 0,00 % | Theratechnologies Reports Financial Results for the Second Quarter 2025 | Q2 2025 total revenue of $17.7 million, and $36.8 million for the first six months of Fiscal 2025Positive Adjusted EBITDA1 for the fifth straight quarterSubsequent to quarter end, Theratechnologies... ► Artikel lesen | |
| ENSYSCE BIOSCIENCES | 2,100 | 0,00 % | Ensysce Biosciences Advances Breakthrough Opioid With Built-In Overdose Protection Following Positive FDA Feedback | ~ Productive FDA Meeting Highlights Path Toward Overdose Protection Labeling and 505(b)(2) Regulatory Strategy ~~ FDA and Ensysce Aligned on Collaborative Approach to Ensure Product's Full Safety Benefits... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 32,745 | 0,00 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution | - ARCALYST® (rilonacept) Q2 2025 net product revenue of $156.8 million, representing 52% year-over-year growth -- ARCALYST 2025 expected net product revenue increased to $625 - $640 million -- KPL-387... ► Artikel lesen | |
| TEVOGEN BIO | 0,864 | +4,60 % | Tevogen Bio Inc: Tevogen Bio Reaffirms Investor Confidence with Estimated Asset Value Exceeding $10 Billion | WARREN, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. ("Tevogen" or the "Company) (Nasdaq: TVGN), reiterates investor confidence and estimated asset value over $10 billion. In... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 46,230 | 0,00 % | Aktien New York: Erholungspfad wieder aufgenommen - Apple ziehen stark an | NEW YORK (dpa-AFX) - Die US-Börsen haben am Mittwoch nach dem etwas schwächeren Vortag wieder den Weg nach oben eingeschlagen. Für Bewegung sorgten positiv aufgenommene Nachrichten zu Apple sowie Unternehmensberichte.... ► Artikel lesen |
ZENAS BIOPHARMA INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 15,900 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ZENAS BIOPHARMA INC finden Sie auf Wallstreet Online.